Pharmaceuticals, biotech, medical devices, and health insurance.
Healthcare combines two very different worlds: established pharmaceutical and health-insurance companies with stable cash flow and dividends, versus research-stage biotech companies whose success or failure hinges on a single event — a clinical trial or FDA approval or rejection. That distinction drives very different risk profiles between companies inside the same sector.
—
Average sector score
8
Stocks analyzed
| # | Company | Score | Rating | Price | Change | |
|---|---|---|---|---|---|---|
| 1 | Kamada Ltd. KMDA | 84 | Strong | $8.87 | +0.2% | Analysis → |
| 2 | Alpha Tau Medical Ltd. DRTS | 81 | Strong | $15.14 | -0.7% | Analysis → |
| 3 | Alvotech ALVO | 81 | Strong | $5.84 | -0.5% | Analysis → |
| 4 | Generate Biomedicines, Inc. GENB | 79 | Strong | $17.46 | +1.9% | Analysis → |
| 5 | TG Therapeutics, Inc. TGTX | 76 | Strong | $58.11 | +2.2% | Analysis → |
| 6 | Eupraxia Pharmaceuticals Inc. EPRX | 75 | Strong | $8.58 | +0.0% | Analysis → |
| 7 | Rigel Pharmaceuticals, Inc. RIGL | 74 | Strong | $48.82 | +4.7% | Analysis → |
| 8 | HUTCHMED (China) Limited HCM | 72 | Strong | $14.07 | +2.9% | Analysis → |
Because much of its value depends on a single regulatory event (clinical trial results, an FDA decision) that can dramatically change its business prospects overnight.
No — an established health-insurance or pharma company with stable cash flow is very different from a trial-stage biotech with no meaningful revenue.
